Trial Information

Summary: A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

This clinical study (The HER2+ Research Study) is examining an investigational medication for safety and effectiveness in slowing the progression of HER2-positive metastatic breast cancer when used in combination with Herceptin and docetaxel.

Study inclusion/exclusion criteria

• At least 18 years old
• Diagnosed with HER2-positive metastatic breast cancer (including people with de-novo Stage IV disease)
• Eligible for chemotherapy

For more information
To learn more about this study, please visit www.HER2researchstudy.com, where you may also take an online prescreener to see if you may be eligible.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 8, 2008 at 12:30:13 PM